rapirosiran (ALN-HSD) / Regeneron 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rapirosiran (ALN-HSD) / Regeneron
NASHGEN-2, NCT05519475: A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Active, not recruiting
2
120
Japan, US, RoW
ALN-HSD, Placebo
Regeneron Pharmaceuticals
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
04/28
12/28
NCT04565717: A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Terminated
1
6
Europe, US, RoW
ALN-HSD, Placebo
Alnylam Pharmaceuticals
Nonalcoholic Steatohepatitis, NASH
01/23
12/23

Download Options